Christopher Whitlow to Immunotherapy
This is a "connection" page, showing publications Christopher Whitlow has written about Immunotherapy.
Connection Strength
0.086
-
Ressler HW, Cramer CK, Isom S, McCormack M, Ruiz J, Xing F, Li W, Whitlow CT, White JJ, Laxton AW, Tatter SB, Chan MD. Brain metastases from renal cell carcinoma: Effects of novel systemic agents on brain metastasis outcomes. Clin Neurol Neurosurg. 2024 Mar; 238:108191.
Score: 0.050
-
Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019 06 12; 11(496).
Score: 0.036